In the News
Heart failure risk prompts warning labels on diabetes drugs
The concern now is whether this particular class of drugs causes other cardiovascular problems.
In May 2007, the FDA told the makers of two diabetes drugs to add "black box" warnings to their labels because of the risk of heart failure. Both medications — Avandia (rosiglitazone), marketed by GlaxoSmithKline, and Actos (pioglitazone), by Takeda Pharmaceuticals — are thiazolidinediones. This class of drugs lowers blood sugar by increasing insulin sensitivity in liver and muscle cells. Insulin is the hormone that moves sugar from the blood into cells. The FDA announced the call for labeling revisions during a Congressional hearing on reports linking Avandia to heart attacks and cardiovascular death.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.